Document is current
Any future updates will be listed below
-
Authors
Bernal, Jhobert
Macalinao, Maria Lourdes
Cosca, Katherine
Boncayao, Beaulah
Mueller, Ivo
Espino, Fe Esperanza J.
Stresman, Gillian
Luchavez, Jennifer
Longley, Rhea J.
-
Funding
Funding for this research was provided by:
Philippine Council for Health Research and Development (2022-03-A2-PCHRD-EASIA-HR-9093, 2022-03-A2-PCHRD-EASIA-HR-9093, 2022-03-A2-PCHRD-EASIA-HR-9093, 2022-03-A2-PCHRD-EASIA-HR-9093)
National Health and Medical Research Council (GNT2018695, GNT2018695)
e-Asia Joint Research Program
National Institute of Allergy and Infectious Diseases (INT-9531011)
Veski
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 7 April 2025
First Online: 16 April 2025
Declarations
:
: All study documents (research protocol, information sheets and written informed consent forms) have been submitted to RITM (Philippines, approved: #2023-17), USF (USA, approved: #STUDY005669) and WEHI (Australia, approved: #HREC23/24) IRBs for ethical approval following local guidelines. Investigators will use the latest Ethics Committee approved version of these documents at all times. The stored blood samples (DBS, EDTA-preserved whole blood, plasma) and datasets that will be collected from this study may be used in the future for new and related research such as surveillance and diagnosis of other diseases of public health importance in the Philippines, and for training of RITM staff on molecular and/or serological assays. A new protocol will be written and IRB approval will be obtained for the use of the samples and/or datasets for the new and related research. Participants will be allowed to withdraw their consent/assent for the storage of their blood samples at any time.
: Not applicable.
: IM and RJL are named inventors on a patent describing P. vivax serological exposure markers (PCT/US17/67926). All other authors declare that they have no competing interests.
